Instalab
Wegovy · semaglutide · once-weekly single-dose pen

~15% weight loss. ~20% fewer cardiovascular events.

The once-weekly GLP-1 injection approved for chronic weight management, and the first proven to cut major cardiovascular events. Prescription, titration, and physician follow-up included.

~15%Mean body weight loss at 68 weeks (STEP-1)
20%Reduction in MACE in CV-risk patients (SELECT)
WeeklySingle-dose pen injection
Wegovy Single-Dose Pen Prescription Review
Wegovy · 0.25 → 2.4mg · single-dose pen · once weekly
Licensed US physician review
12,000+ patients treated
Available in all 50 states
Ongoing titration and follow-up
How it works

From questionnaire to first injection.

No clinic visits. A licensed physician reviews your case, picks the right starting dose, and manages each titration step. We handle refills and follow-up.

Step 1

2-minute questionnaire

Tell us about your weight history, BMI, related conditions, prior GLP-1 use, and goals.

Step 2

Physician review

A licensed physician confirms eligibility, screens for contraindications (MTC/MEN 2, pancreatitis history, gastroparesis), and writes your starting prescription. Usually within 1 business day.

Step 3

Cost check and dispensing

We verify insurance and file prior authorization. If self-pay makes more sense, we shop pharmacy options.

Step 4

Titration and follow-up

Start at 0.25mg weekly for 4 weeks. Step up every 4 weeks: 0.5mg, 1mg, 1.7mg, then 2.4mg maintenance. We monitor side effects, manage refills, and time each dose increase.

Pricing

What you'll actually pay.

Two line items: Instalab Membership and the Wegovy medication itself, dispensed by your pharmacy.

Instalab Membership

Physician oversight, titration management, ongoing follow-up

$—/mo

Wegovy (semaglutide injection)

Brand-name only, dispensed by your pharmacy

Cash price$349/monthTypical brand cash price
With insurance$25–100/monthTypical copay, if covered

Why pay a membership fee? Wegovy needs a physician who manages titration, side effects, and metabolic monitoring across 5 monthly dose steps. Membership covers visits, renewals, prior authorization, and pharmacy coordination. Insurance coverage for weight loss varies dramatically; cash price is high because no generic exists.

Will my insurance cover Wegovy?

Coverage for Wegovy varies dramatically by plan. Some commercial plans cover it when BMI and weight-related condition criteria are met; some plans exclude weight-loss medications entirely. The 2024 FDA-approved CV-reduction indication has expanded coverage in some plans for patients with established cardiovascular disease and overweight or obesity. Medicare currently does not cover GLP-1s for weight loss alone but may cover for the CV-reduction indication in eligible patients. We check your plan and file prior authorization either way.

Why membership

Wegovy works. Titration and follow-up take ongoing care.

It needs a physician who manages dose increases, side effects, and metabolic monitoring across the 5-step titration. Here's how our team handles that for you.

  1. Week 1Day 1–5

    Physician evaluation and prescription

    A licensed physician reviews your weight history, BMI, related conditions, and goals, then writes your starting prescription at 0.25mg weekly. We verify insurance and file prior authorization in parallel.

  2. Week 2

    First injection at home

    Your Wegovy single-dose pen ships from the pharmacy. We walk you through self-injection and check in after your first dose.

  3. Week 4+

    Monthly titration

    Step up monthly: 0.25 → 0.5 → 1 → 1.7 → 2.4mg. We coordinate each refill with the new dose so you never run short.

  4. OngoingMonth 6+

    Ongoing care and renewals

    Your physician tracks weight, side effects, and metabolic labs over time. Most patients reach 15% body weight loss by month 12 to 16. We keep your prescription, prior authorization, and pharmacy on the same page.

Without membership

Schedule a PCP or obesity-medicine visit. Wait months. Chase prior auth and refills yourself. Manage side effects between appointments.

With Instalab

2-minute questionnaire. Physician review within 1 business day. Insurance and titration handled. Refills and side-effect check-ins built in.

About the medication

One injection a week.

Wegovy is a once-weekly subcutaneous injection from a single-dose pre-filled pen. Same day each week. Stomach, thigh, or upper arm.

  • Single-dose pen, once weeklyEach pen contains one weekly dose. Click and hold, done. A new pen every week.
  • Pick a weekday, any time of dayTake it the same day each week. Day-of-week consistency matters more than time-of-day.
  • 5-step titration over ~5 monthsStart at 0.25mg, step up monthly through 0.5, 1.0, 1.7, and finally 2.4mg maintenance. The lower doses are for titration, not weight loss.
  • Ongoing physician supportYour care team is a message away for nausea, dose timing, and metabolic monitoring across the plan.
Why Wegovy

The first GLP-1 with an FDA-approved CV-risk-reduction label for weight.

Wegovy is semaglutide at higher doses, FDA-approved for chronic weight management in 2021 (STEP-1 trial). In 2024, the FDA expanded the label to include reducing the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity — based on the SELECT trial, which randomized 17,604 patients and showed a 20% reduction in major adverse cardiovascular events over a mean 40 months. It is the first weight-loss medication ever to carry a CV-risk-reduction indication.

  • ~15% mean body weight loss at 68 weeksIn STEP-1, adults with obesity (or overweight with weight-related conditions) and without diabetes lost a mean 14.9% of body weight on Wegovy 2.4mg over 68 weeks, versus 2.4% on placebo.
  • 20% reduction in major cardiovascular eventsSELECT randomized 17,604 adults with established CVD and overweight or obesity, without diabetes, to Wegovy or placebo. Over a mean 40 months, semaglutide reduced the composite of CV death, MI, and stroke by 20%. This drove the 2024 FDA expansion.
  • Same molecule as Ozempic, higher doseSemaglutide is semaglutide. The difference between Wegovy and Ozempic is the maximum approved dose (2.4mg vs 2mg) and the indication (weight loss with CV reduction vs T2D with CV reduction). The molecule and mechanism are identical.

The STEP-1 and SELECT trials

STEP-1 (NEJM 2021) established the weight-loss efficacy of semaglutide 2.4mg: 1,961 adults with obesity, mean 14.9% weight loss at 68 weeks versus 2.4% on placebo. SELECT (NEJM 2023) established the CV benefit: 17,604 adults with established CVD and overweight or obesity, 20% reduction in major cardiovascular events over a mean 40 months. Together they make Wegovy the first weight-loss medication with an FDA-approved CV-reduction indication.

~15%
Mean weight loss at 68 weeks (STEP-1)
20%
MACE reduction (SELECT)
17,604
Patients in the SELECT CV trial

Wegovy is a prescription medicine. Important safety information applies. The most common side effects are gastrointestinal. There is a boxed warning for thyroid C-cell tumors, based on rodent studies.

Ready when you are

Lose weight. Cut CV risk.

Answer the questionnaire. A physician reviews your case and, if Wegovy is appropriate, prescribes it. We handle titration, refills, and follow-up.

No commitment to treatment.